Register now! How artificial intelligence can help researchers? Insilico hosts webinar “IMGAIA”

Artificial intelligence (AI) has swiftly revolutionized numerous industries, and the life sciences sector is no exception. The growing power and capability of AI present immense opportunities for advancing research and development. However, the challenge lies in harnessing this potential effectively: How can we leverage AI to maximize its benefits in the life sciences?

On July 23rd, 2pm EDT in a Virtual Launch Event, Insilico is going to unveil three innovative in-house developed AI products for researchers as well as introduce the updates to Pharma.AI, the company’s proprietary generative AI-driven platform for early drug research. In addition, we will introduce our new advanced sustainability initiative driven by AI. The event will include a Q&A session for attendees. 

The new products include:

-Science42：DORA, an advanced large language model-driven AI assistant, designed to streamline the process of drafting academic papers and other related documents.

-Biology42：PandaOmics Box, an AI-powered converged research platform, for localized biological research in target identification, biomarker discovery, and indication prioritization.

-Biology42：Precious-3 GPT, a transformer-based LLM engine across multi-modal, multi-omics, multi-species for biomedical research through omics data generation and interpretation.

Since its industry-first description of the concept of applying generative AI to drug discovery and development in a peer-reviewed paper in 2016, Insilico has built Pharma.AI, the generative AI-driven platform connecting biology, chemistry, medicine, and science to solve complex challenges in life sciences, by accelerating drug development, enhancing precision medicine and supporting anti-aging research. All the innovative products above are new additions to the Pharma.AI platform.

In the past few years, Insilico has optimized and validated its Pharma.AI platform through internal drug pipeline development and external R&D collaborations. 

Currently, 10 of the world’s top 20 pharmaceutical companies use Pharma.AI. Powered by the platform, Insilico has nominated 18 preclinical candidates in its comprehensive portfolio of over 30 assets since 2021, and has received IND approval for 7 molecules. Recently, the company published a paper in Nature Biotechnology presenting the entire R&D journey of its lead drug pipeline, INS018_055, from AI algorithms to Phase II clinical trials.

“At Insilico, we are committed to continually expanding the boundaries of AI applications and applying them to all aspects of life sciences to accelerate drug discovery, empower anti-aging research, and support sustainable development,” said Alex Zhavoronkov, founder and CEO of Insilico Medicine, “ These new product launches are expected to help life science researchers accomplish their tasks more easily and efficiently. This is the true promise of genAI.”

About Insilico Medicine

Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. 

www.insilico.com